Blood loss is a major cause of iron deficiency in adults. Some sources of chronic blood loss in adults are all except:

A. The patient experiences a decrease in hemoglobin S. Hydroxyurea does not decrease hemoglobin S levels directly; it works by increasing fetal hemoglobin (Hgb F) levels.
B. The patient experiences dehydration due to diuresis. This is not an indication that Hydroxyurea is working; it is a potential side effect that should be monitored.
C. The patient experiences an increase in fetal hemoglobin (Hbg F). Hydroxyurea works by increasing the levels of fetal hemoglobin, which reduces the sickling of red blood cells.
D. The patient needs fewer blood transfusions. Successful treatment with Hydroxyurea should reduce the frequency of vaso-occlusive crises and the need for blood transfusions.
E. The patient experiences diuresis. This is not an indicator of the medication's effectiveness; it is a potential side effect.

A. Skin color: While changes in skin color can occur in hemochromatosis due to excess iron deposition, it is not the most important parameter to monitor for the effectiveness of deferoxamine.
B. Liver function: Liver function tests can be abnormal in hemochromatosis due to iron overload, but monitoring liver function alone may not adequately assess the effectiveness of deferoxamine in reducing iron levels.
C. Hematocrit: Hematocrit measures the proportion of blood that is made up of red blood cells and may be elevated in hemochromatosis, but it is not the primary parameter to monitor the effectiveness of deferoxamine.
D. Serum iron level: Serum iron level is the most direct indicator of iron overload and the effectiveness of deferoxamine in chelating and removing excess iron from the body.